Stockscreener 앱 받기
0.00
100.00%
-14.49
시간 외 거래:
14.49
14.49
+
전일 마감가:
$14.49
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$4.55B
수익:
$634.21M
순이익/손실:
$-27.11M
주가수익비율:
0.00
EPS:
-0.0885
순현금흐름:
$29.85M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$14.50
아미쿠스 테라 Stock (FOLD) Company Profile
명칭
Amicus Therapeutics Inc
전화
(609) 662-2000
주소
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
0.00 | 4.55B | 634.21M | -27.11M | 29.85M | -0.0885 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
아미쿠스 테라 Stock (FOLD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-29 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-12-22 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-12-17 | 개시 | Citigroup | Buy |
| 2025-09-18 | 업그레이드 | Needham | Hold → Buy |
| 2025-07-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | 개시 | Jefferies | Buy |
| 2024-05-30 | 개시 | Wells Fargo | Overweight |
| 2024-05-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-04-13 | 재개 | Goldman | Neutral |
| 2022-01-14 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-30 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-07-19 | 재개 | BTIG Research | Buy |
| 2021-05-27 | 개시 | Needham | Hold |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | 개시 | Stifel | Hold |
| 2021-02-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 재개 | Cantor Fitzgerald | Overweight |
| 2020-12-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-02-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-11-12 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-17 | 개시 | H.C. Wainwright | Buy |
| 2019-06-05 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-04-05 | 개시 | Janney | Buy |
| 2019-01-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-10-29 | 개시 | Citigroup | Neutral |
| 2018-08-17 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
| 2017-09-13 | 재확인 | Chardan Capital Markets | Buy |
| 2017-08-10 | 재확인 | Chardan Capital Markets | Buy |
| 2017-01-24 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | 개시 | BofA/Merrill | Buy |
| 2016-04-14 | 개시 | Robert W. Baird | Neutral |
| 2016-04-12 | 재확인 | Chardan Capital Markets | Buy |
| 2015-09-16 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | 재확인 | Chardan Capital Markets | Buy |
모두보기
아미쿠스 테라 주식(FOLD)의 최신 뉴스
Amicus Therapeutics Inc (FOLD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amicus Therapeutics Inc (FOLD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Amicus Therapeutics Q2 2025 Earnings Preview - MSN
Amicus Therapeutics Stock (US03152W1099): valuation picture in focus for biotech name FOLD - AD HOC NEWS
John Paulson’s fund initiates Amicus Therapeutics position, dumps SOLS among Q1 moves - MSN
Amicus Therapeutics stock (US03152W1099): analysts see limited upside after strong run - AD HOC NEWS
Are Amicus Therapeutics (FOLD) and Autoliv (ALV) Overlooked Opportunities - Kavout
Paulson & Co. Acquires Amicus Therapeutics (FOLD) and Exits Solstice Advanced Materials (SOLS) - GuruFocus
Barclays holds 17.8M Amicus shares (NASDAQ: FOLD), 5.65% stake - Stock Titan
Amicus Therapeutics stock (US03152W1099): Biotech focused on rare diseases - AD HOC NEWS
FOLD SEC FilingsAmicus Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Goldman Sachs (FOLD) discloses 16.78M shares, 5.3% ownership (Schedule 13G) - Stock Titan
Fabry Disease Treatment Market to Reach USD 3,530.5 Million - openPR.com
BioMarin Q1 earnings miss, sales beat, '26 revenue guidance raised - MSN
Amicus Therapeutics (Delisted) | SCHEDULE 13G: Others - Moomoo
UBS Group-affiliated funds hold 17.14M shares in Amicus Therapeutics (NASDAQ: FOLD) - Stock Titan
[15-12G] AMICUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Which Is a Better Investment, AnaptysBio, Inc. or Amicus Therapeutics, Inc. Stock? - AAII
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition (NASDAQ:BMRN) - Seeking Alpha
BioMarin acquires Amicus Therapeutics for $4.8bn - MSN
MSN Money - MSN
BioMarin to buy rare disease drugmaker Amicus Therapeutics for $4.8B - MSN
BioMarin beats estimates, raises guidance on Amicus deal By Investing.com - Investing.com South Africa
BioMarin beats estimates, raises guidance on Amicus deal - Investing.com
BioMarin Reports First Quarter 2026 Financial and Operating Results - Santa Maria Times
UBS Group AG Grows Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
CM Management LLC Has $5.27 Million Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin Amicus Deal Expands Rare Disease Reach And Adds Kidney Asset - Sahm
Glazer Capital (FOLD) reports zero holdings after falling below 5% stake - Stock Titan
Pictet Asset Management Holding SA Trims Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Decreases Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin Closes Amicus Deal As FOLD Delists And Indices Adjust - Sahm
[EFFECT] AMICUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Amicus Therapeutics (FOLD) Expected to Announce Earnings on Thursday - MarketBeat
Amicus Therapeutics, Inc. Financial Disclosures & Filings - TradingView
Vanguard Capital Management holds 5.20% of Amicus Therapeutics (NASDAQ: FOLD) - Stock Titan
Amicus Therapeutics, Inc.(NasdaqGM: FOLD) dropped from S&P Global BMI Index - marketscreener.com
Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
BioMarin closes $4.8B Amicus deal to boost rare disease portfolio - MSN
아미쿠스 테라 (FOLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):